Filetype
Årsrapport 2004 för Enheten för medicinens historia, Medicinska Fakulteten, Lunds universitet 1 Årsrapport 2019 för Enheten för medicinens historia, Medicinska Fakulteten, Lunds universitet Enheten för medicinens historia har under året 2019 fortsatt sin verksamhet som en fristående enhet inom Institutionen för kliniska vetenskaper (IKVL) i Lund (prefekt Mikael Bodelsson, sektion 5 med chef Håkan
Brevmall Ansvarig för uppdatering: HR-funktionen, Kansli EHL (personal@ehl.lu.se) Kans l i EHL, HR-funkt ionen Frågor och svar om bisysslor Bisysslor ................................................................................................................ 1 Registrering av bisyssla ......................................................................................... 2 Gränser och ansvar
https://www.lusem.lu.se/internal/sites/lusem.lu.se.internal/files/2024-01/fragor-svar-bisysslor.pdf - 2025-11-12
Universitetslektor Kontaktinformation E-post: elsa [dot] trolle_onnerfors [at] jur [dot] lu [dot] se Telefon: +46 46 222 10 97Organisation Juridiska institutionen Rumsnummer: 332 Hämtställe: 56 WebbplatsElsa Trolle Önnerfors profil i Lunds universitets forskningsportalAndra roller Forskare Rättshistoria Docent Juridiska institutionen Publikationer Visar av publikationer. Sorterade efter år och sen
https://www.jur.lu.se/elsa-trolle-onnerfors - 2025-11-13
Forskare Kontaktinformation E-post: jagdeep [dot] singh [at] cec [dot] lu [dot] se Telefon: +46 46 222 47 42Organisation Centrum för miljö- och klimatvetenskap (CEC) Besöksadress: Ekologihuset, Sölvegatan 37, Lund Rumsnummer: C 354 Hämtställe: 50 WebbplatsJagdeep Singhs profil i Lunds universitets forskningsportalAndra roller Forskare BECC: Biodiversity and Ecosystem services in a Changing Climate
https://www.cec.lu.se/sv/jagdeep-singh - 2025-11-13
Nationalekonomiska institutionen Institutionens studievägledare handhar vägledning och rådgivning angående studier i nationalekonomi, alltifrån grundkurser till kurser på avancerad nivå. Om du har problem med dina studier, har frågor om kursval eller studieupplägg, tillgodoräknande av kurser, behörigheter, examenskrav eller om du har andra relevanta frågor så är du varmt välkommen att kontakta stu
https://www.ehl.lu.se/organisation/nationalekonomiska-institutionen/studera-nationalekonomi/studievagledning - 2025-11-12
Universitetslektor Kontaktinformation E-post: luciana [dot] quaranta [at] ekh [dot] lu [dot] se Telefon: +46 46 222 04 97Organisation Ekonomisk-historiska institutionen Besöksadress: Scheelevägen 15 B, Lund Rumsnummer: Alfa 1:2019 Hämtställe: 10 WebbplatsLuciana Quarantas profil i Lunds universitets forskningsportalAndra roller Universitetslektor Ekonomisk demografi Profilområdesmedlem LU profilom
https://www.ehl.lu.se/luciana-quaranta - 2025-11-13
Språk- och litteraturcentrum Litteraturlista för KINM13 ”RÖDA LISTAN”: FÖRDJUPNING I KANSLISPRÅKLIG KINESISKA, 15 hp Fastställd av Lärarkollegium 5, 2014-03-31. Reviderad av styrelsen för Sektion 5 2021-11-24 --------------------------------------------------------------------------------------------------------------------------- 2021年3月26日外交部发言人华春莹主持例行记者会 (Utrikesministeriets talesperson Hua Chu
https://www.sol.lu.se/media/utbildning/dokument/kurser/KINM13/20232/KINM13_litteraturlista_23.docx - 2025-11-11
Styrelsen | Akademikerföreningen vid Siemens Energy AB Hoppa till huvudinnehåll Öppna sökruta Öppna Huvudmeny Sök på saco.se Om oss Stadgar Kollektivavtal Bli medlem Nyheter Årsmöte 2025 Nyhetsbrev Presentationsmaterialet från pensionsföreläsningen 15/10 Pensionsföreläsning 15/10-2025 kl.08 Löneskola 2025 Möt ASI-styrelsen över en kopp kaffe Ny styrelsesammansättning Förtroendevalda Vårt uppdrag M
Research in the Area of Clouds, Aerosols and Climate The research group of Phillips is tackling a range of issues, such as ice initiation in clouds, effects on precipitation from bio-aerosols, and development of new technologies for representing clouds in global climate models. Contact details Email: vaughan [dot] phillips [at] nateko [dot] lu [dot] se Phone: +46 46 222 17 32Organisation Dept of P
https://www.nateko.lu.se/vaughan-phillips - 2025-11-13
BACKGROUND Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study. METHODS We randomly assigned 418 previously untreated patients who had metastatic melanoma w
Purpose: To compare rates of tau biomarker positivity (T-status) per the 2018 Alzheimer’s Disease (AD) Research Framework derived from [18F]flortaucipir (FTP) PET visual assessment, FTP quantification, and cerebrospinal fluid (CSF) phosphorylated Tau-181 (PTau181). Methods: We included 351 subjects with varying clinical diagnoses from three cohorts with available FTP PET and CSF PTau181 within 18
Introduction: Reporting of hypoglycaemia and its impact in clinical studies is often retrospective and subject to recall bias. We developed the Hypo-METRICS app to measure the daily physical, psychological, and social impact of hypoglycaemia in adults with type 1 and insulin-treated type 2 diabetes in real-time using ecological momentary assessment (EMA). To help assess its utility, we aimed to de
Aims/hypothesis: The aim of this work was to examine the impact of hypoglycaemia on daily functioning among adults with type 1 diabetes or insulin-treated type 2 diabetes, using the novel Hypo-METRICS app. Methods: For 70 consecutive days, 594 adults (type 1 diabetes, n=274; type 2 diabetes, n=320) completed brief morning and evening Hypo-METRICS ‘check-ins’ about their experienced hypoglycaemia a
Hypomethylating agents (HMAs) are frontline therapies for Myelodysplastic Neoplasms (MDS) and Acute Myeloid Leukemia (AML). However, acquired resistance and treatment failure are commonplace. To address this, we perform a genome-wide CRISPR-Cas9 screen in a human MDS-derived cell line, MDS-L, and identify TOPORS as a loss-of-function target that synergizes with HMAs, reducing leukemic burden and i
Background Although human leukocyte antigen (HLA) DQ and DR loci appear to confer the strongest genetic risk for type 1 diabetes, more detailed information is required for other loci within the HLA region to understand causality and stratify additional risk factors. The Type 1 Diabetes Genetics Consortium (T1DGC) study design included high-resolution genotyping of HLA-A, B, C, DRB1, DQ, and DP loc
Allergic immunity is orchestrated by group 2 innate lymphoid cells (ILC2s) and type 2 helper T (Th2) cells prominently arrayed at epithelial- and microbial-rich barriers. However, ILC2s and Th2 cells are also present in fibroblast-rich niches within the adventitial layer of larger vessels and similar boundary structures in sterile deep tissues, and it remains unclear whether they undergo dynamic r
The intronic SNP rs7903146 in the T-cell factor 7-like 2 gene (TCF7L2) is the common genetic variant most highly associated with Type 2 diabetes known to date. The risk T-allele is located in an open chromatin region specific to human pancreatic islets of Langerhans, thereby accessible for binding of regulatory proteins. The risk T-allele locus exhibits stronger enhancer activity compared to the n
Pancreatic islets are complex micro-organs consisting of at least three different cell types: glucagon-secreting alpha, insulin-producing beta and somatostatin-releasing delta cells. Somatostatin is a powerful paracrine inhibitor of insulin and glucagon secretion. In diabetes, increased somatostatinergic signalling leads to defective counter-regulatory glucagon secretion. This increases the risk o
Swelling of the brain or spinal cord (CNS edema) affects millions of people every year. All potential pharmacological interventions have failed in clinical trials, meaning that symptom management is the only treatment option. The water channel protein aquaporin-4 (AQP4) is expressed in astrocytes and mediates water flux across the blood-brain and blood-spinal cord barriers. Here we show that AQP4
Acute myeloid leukemia with t(6; 9)(p22; q34) is listed as a distinct entity in the 2008 World Health Organization classification, but little is known about the clinical implications of t(6; 9)-positive myeloid leukemia in children. This international multicenter study presents the clinical and genetic characteristics of 62 pediatric patients with t(6; 9)/DEKNUP214-rearranged myeloid leukemia; 54
